R vs SAS for Clinical Trials in 2026: An Honest Comparison for Decision-Makers
- Regulatory acceptance is no longer the differentiator. The FDA requires no specific software and has received fully R-based pilot submissions; the EMA position is equivalent. Both languages are acceptable with a controlled process.
- The validation burden is similar in kind and different in ownership. SAS users rely partly on the vendor’s quality system; R users document their own environment, package and QC controls. The R evidence tends to be more transparent once set up.
- The ecosystem gap has closed for ADaM and TLFs (admiral, rtables, tern, gtsummary, xportr). It has not fully closed for some legacy sponsor macro libraries, which is where migration effort goes.
- The realistic choice for most CROs is coexistence with a managed migration, not a switch-over date.
Programmers argue about syntax. Decision-makers need to know what changes for the business, the quality system and the sponsor relationship. This comparison tries to be fair to both tools as they stand in 2026.
Regulatory acceptance
SAS: decades of precedent; reviewers are familiar with its outputs and transport files.
R: the FDA’s Statistical Software Clarifying Statement has long said no specific software is required. The R Consortium’s R Submissions Working Group has completed multiple pilot submissions, including fully R-based ADaM and TLF packages and a Shiny application run inside the agency’s environment. Reviewers now see R code in real submissions. Details in Is R accepted by the FDA?.
Verdict: both acceptable. Acceptance depends on process evidence, not the language.
Validation
SAS: the vendor provides installation qualification tooling and a quality statement; sponsors still own user-level validation of macros and programs.
R: the organisation owns environment qualification (renv, test-suite runs), package qualification (riskmetric, decision records) and process controls. See how to write an R validation plan and qualifying R packages.
Verdict: more set-up work in R, after which the evidence is explicit and automated. Teams that treated SAS as “validated by default” sometimes discover their macro libraries were never qualified to the standard they now apply to R. That is a finding about the past, not about R.
Ecosystem for clinical work
| Need | SAS | R (2026) |
|---|---|---|
| SDTM | Established sponsor/CRO macros | sdtm.oak and sponsor code; less mature than ADaM tooling |
| ADaM | PROC/macro libraries | admiral family, metacore/metatools for metadata-driven derivations |
| TLFs | PROC REPORT, ODS, sponsor macros | rtables + tern (Roche-origin), gtsummary, Tplyr; RTF/DOCX output |
| Transport files | PROC CPORT/XPORT | xportr with validation against specs |
| Define.xml | Vendor tools | Generation from metadata in R, often paired with vendor tools |
| Survival, mixed models | PROC LIFETEST/PHREG/MIXED | survival, nlme/lme4, mmrm (designed for regulatory use) |
| Bayesian and adaptive designs | Limited | Strong (brms, rstan, gsDesign, rpact) |
| Interactive review | Limited | Shiny, including the FDA pilot precedent |
Verdict: parity for the core submission deliverables; R ahead for methods and interactivity; SAS ahead wherever a sponsor’s institutional macro library is the de facto standard.
Equivalence of results
The two systems agree to numerical precision for almost everything when the same method is specified. Where they differ, the cause is a default rather than an error: rounding conventions, missing-value semantics, percentile definitions, sums-of-squares types, tie handling. Every one of these is resolvable and documentable; the tolerance rules exist for that purpose.
Verdict: no statistical reason to prefer either; a process reason to document defaults.
Talent and training
SAS: a shrinking but experienced pool, concentrated in pharma and CROs; new graduates rarely learn it first.
R: the default in statistics departments and increasingly in biostatistics programmes; the pharmaverse community trains clinical-specific skills. Experienced SAS programmers typically become productive in R within months when trained on their own studies rather than on toy examples.
Verdict: the long-run talent trend favours R; the short-run cost is retraining a team that knows your macros.
Cost
SAS: licensing is a significant recurring line, plus infrastructure.
R: no licence; costs move to qualification effort, internal package maintenance, and optionally commercial support or platforms (Posit, cloud environments). Migration itself is a one-off project cost whose size depends on the macro library; see the five-phase roadmap.
Verdict: R is cheaper at steady state for most organisations; the transition has a real price that should be estimated from an inventory, not assumed.
Risks on each side
Risk of migrating: disruption to live deliverables if the pilot is not isolated; inconsistent conversions if standards are not set first; a validation gap if documentation is left to the end. Each is mitigated by sequencing, which is what the roadmap is for.
Risk of not migrating: rising licence and talent costs; increasing sponsor requests for R deliverables or R-literate review; dependence on a macro library whose authors have left. These risks grow quietly.
What we recommend to most CROs
- Run a Phase 1 assessment: inventory, risk classification, macro reuse map. Two to six weeks, fixed scope. The findings replace speculation about cost.
- Pilot on a closed study, parallel-run against SAS, with tolerance rules decided up front.
- Build the package layer and the validation documentation once, then move studies in order of reuse.
- Keep SAS where it is cheap to keep (rarely run legacy programs) and retire it where it is expensive (shared macros under active maintenance).
- Prepare the sponsor and regulatory narrative early, grounded in the FDA statement, the pilot submissions and your own evidence.
Coexistence is normal. A managed migration is a programme, not a leap. If you would like a second opinion on an existing plan or help with Phase 1, the SAS to R migration page explains how we work and how to reach us.